EWPI Emerging World Pharma Inc (CE)

Emerging World Pharma Inc. (PINKSHEETS: EWPI) has been granted an investment option to increase their percentage of profits by up to 25%. Emerging World Pharma had provided an initial investment to African Global Pharma, a division of Global Pharma Corp. operating in West Africa. As per the first agreement the investment would entitle Emerging World Pharma a percentage of profits obtained from an exclusive marketing and distribution agreement from the generic pharmaceutical manufacturer.

This is a region with a population of approximately 250 million. Nigeria's Pharmaceutical market serving 150 million Nigerians is worth $2.5 billion.

"This is a tremendous opportunity that has been presented to us at this early juncture. The business relationship and confidence that we have developed with African Pharma Corp. in such a short period of time is incredible. We believe this will be a long term business association with them in the global generic pharmaceutical market," noted Emerging World Pharma president, Brandon Keks.

Keks, who recently returned from a gratifying tour of the African Global Pharma (AGP) manufacturing facilities, added that AGP has an exclusive marketing and distribution agreement with a highly reputable organization that will be the sole distributor and will market AGP products to other private and public hospitals and pharmacies. The company will provide the specifics of the parties involved in this agreement in a subsequent press release.

www.emergingpharma.com

About Emerging World Pharma Inc.

Emerging World Pharma Inc. is an investor in generic based pharmaceutical companies manufacturing within developing nations.

The company focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups; church, government and wholesalers. Market research shows that these branches are the most secure, protected and reputable for the distribution of medicines.

About Global Pharma Corp.

Since 1996 Global Pharma has been producing top quality USP generics at competitive prices based on a low overhead corporate model. We choose to provide advanced pharmaceutical solutions to our customers which directly translates to cost savings when compared to our competitors.

Our strengths are:

• Skilled and Experienced Teams
• State of the art Production Machinery and Technology
• Regular Manufacturing Upgrades
• Superior Quality
• Affordable Prices
• In-house Quality Control Lab
• Qualified & Dedicated Management and quality control
• Ability to fill Bulk Demand orders

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

Contact: Joel Everret Emerging World Pharma Inc. Investor Relations Division 703-646-2633 Email: info@emergingpharma.com